The emergence of Retatrutide ZPHC, at a strength of 120mg, is generating considerable buzz within the medical community. This novel dual GIP and GLP-1 agonist medication appears to provide significant improvements in fat loss compared to existing therapies. Initial clinical data have indicated marke